Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Theratechnologies Inc

+ Add to Watchlist

TQ8:GR

0.544 EUR 0.031 6.04%

As of 09:35:07 ET on 03/04/2015.

Snapshot for Theratechnologies Inc (TQ8)

Open: 0.544 Day's Range: 0.544 - 0.544 Volume: 0
Previous Close: 0.513 52wk Range: 0.193 - 0.563 1-Yr Rtn: +105.28%

Stock Chart for TQ8

No chart data available.
  • TQ8:GR 0.544
  • 1D
  • 1M
  • 1Y
0.513
Interactive TQ8 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TQ8

Current P/E Ratio (ttm) -
Estimated P/E(11/2014) -
Relative P/E vs. DAX -
Earnings Per Share (CAD) (ttm) -
Est. EPS (CAD) (11/2014) -0.2030
Est. PEG Ratio -
Market Cap (M EUR) 33.19
Shares Outstanding (M) 61.01
30 Day Average Volume 265
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TQ8

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for TQ8

Theratechnologies, Inc. is a specialty pharmaceutical company that discovers and develops therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. The Company's main product is being marketed in the United States for the reduction of excess abdominal fat n HIV-infected patients with lipodystrophy.

Luc TanguayPres/CEO/Investor RelationsLyne FortinSenior VP/Chief Commercial Ofcr
Christian MarsolaisSenior VP:Scientific AffairsMarie-Noel ColussiVP:Finance
More Company Profile & Key Executives for TQ8

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil